149 related articles for article (PubMed ID: 26831403)
1. Effect of adiponectin-encoding gene ADIPOQ single nucleotide polymorphisms +45 and +276 on serum lipid levels after antiretroviral therapy in Japanese patients with HIV-1-infection.
Kato H; Ohata A; Samukawa S; Ueda A; Ishigatsubo Y
J Int Med Res; 2016 Apr; 44(2):297-306. PubMed ID: 26831403
[TBL] [Abstract][Full Text] [Related]
2. Impact of genetic factors on dyslipidemia in HIV-infected patients starting antiretroviral therapy.
Egaña-Gorroño L; Martínez E; Cormand B; Escribà T; Gatell J; Arnedo M
AIDS; 2013 Feb; 27(4):529-38. PubMed ID: 23262498
[TBL] [Abstract][Full Text] [Related]
3. Association of single-nucleotide polymorphisms in TLR7 (Gln11Leu) and TLR9 (1635A/G) with a higher CD4T cell count during HIV infection.
Said EA; Al-Yafei F; Zadjali F; Hasson SS; Al-Balushi MS; Al-Mahruqi S; Koh CY; Al-Naamani K; Al-Busaidi JZ; Idris MA; Balkhair A; Al-Jabri AA
Immunol Lett; 2014 Jul; 160(1):58-64. PubMed ID: 24747071
[TBL] [Abstract][Full Text] [Related]
4. Polymorphisms in adiponectin receptor genes are associated with lipodystrophy-related phenotypes in HIV-infected patients receiving antiretroviral therapy.
Castilhos JK; Sprinz E; Lazzaretti RK; Kuhmmer R; Mattevi VS
HIV Med; 2015 Sep; 16(8):494-501. PubMed ID: 26111083
[TBL] [Abstract][Full Text] [Related]
5. Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.
Keiser PH; Sension MG; DeJesus E; Rodriguez A; Olliffe JF; Williams VC; Wakeford JH; Snidow JW; Shachoy-Clark AD; Fleming JW; Pakes GE; Hernandez JE;
BMC Infect Dis; 2005 Jan; 5():2. PubMed ID: 15647105
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of switch to atazanavir-containing combination antiretroviral therapy in HIV-1-infected patients with hyperlipidemia.
Lu CL; Lin YH; Wong WW; Lin HH; Ho MW; Wang NC; Hsieh SM; Sheng WH; Hung CC; Chen MY
J Microbiol Immunol Infect; 2011 Aug; 44(4):258-64. PubMed ID: 21524961
[TBL] [Abstract][Full Text] [Related]
7. Contribution of genetic background and antiretroviral therapy to body fat changes in antiretroviral-naive HIV-infected adults.
Egaña-Gorroño L; Martínez E; Pérez I; Escribà T; Domingo P; Gatell JM; Arnedo M
J Antimicrob Chemother; 2014 Nov; 69(11):3076-84. PubMed ID: 25185137
[TBL] [Abstract][Full Text] [Related]
8. Switch from unboosted protease inhibitor to a single-tablet regimen containing rilpivirine improves cholesterol and triglycerides.
Di Biagio A; Riccardi N; Taramasso L; Capetti A; Cenderello G; Signori A; Vitiello P; Guerra M; de Socio GV; Cassola G; Quirino T; Viscoli C
Int J Antimicrob Agents; 2016 Nov; 48(5):551-554. PubMed ID: 27566908
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir-boosted saquinavir. The CIVSA Study.
Mallolas J; Blanco J; Labarga P; Vergara A; Ocampo A; Sarasa M; Arnedo M; López-Púa Y; García J; Juega J; Guelar A; Terrón A; Dalmau D; García I; Zárraga M; Martínez E; Carné X; Pumarola T; Escayola R; Gatell J
HIV Med; 2007 May; 8(4):226-33. PubMed ID: 17461850
[TBL] [Abstract][Full Text] [Related]
10. Lipid levels in the second year of life among HIV-infected and HIV-exposed uninfected Latin American children.
Hazra R; Cohen RA; Gonin R; Monteiro JP; Hofer CB; Negra MD; Ruz NP;
AIDS; 2012 Jan; 26(2):235-40. PubMed ID: 22008654
[TBL] [Abstract][Full Text] [Related]
11. Serum adiponectin and metabolic parameters in HIV-1-infected patients after substitution of nevirapine for protease inhibitors.
Petit JM; Duong M; Masson D; Buisson M; Duvillard L; Bour JB; Brindisi MC; Galland F; Guiguet M; Gambert P; Portier H; Vergès B
Eur J Clin Invest; 2004 Aug; 34(8):569-75. PubMed ID: 15305892
[TBL] [Abstract][Full Text] [Related]
12. Indinavir/ritonavir-based therapy in HIV-1-infected antiretroviral therapy-naive patients: comparison of 800/100 mg and 400/100 mg twice daily.
Konopnicki D; De Wit S; Poll B; Crommentuyn K; Huitema A; Clumeck N
HIV Med; 2005 Jan; 6(1):1-6. PubMed ID: 15670245
[TBL] [Abstract][Full Text] [Related]
13. Lipid peroxidation and total cholesterol in HAART-naïve patients infected with circulating recombinant forms of human immunodeficiency virus type-1 in Cameroon.
Teto G; Kanmogne GD; Torimiro JN; Alemnji G; Nguemaim FN; Takou D; Nanfack A; Tazoacha A
PLoS One; 2013; 8(6):e65126. PubMed ID: 23762297
[TBL] [Abstract][Full Text] [Related]
14. Association of immune recovery with hyperlipidaemia and apolipoprotein gene polymorphisms following highly active antiretroviral therapy in a cohort of Chinese HIV patients.
Chan DP; Lee MP; Wong NS; Leung RK; Naftalin CM; Lee SS
BMJ Open; 2016 Apr; 6(4):e010998. PubMed ID: 27067897
[TBL] [Abstract][Full Text] [Related]
15. Persistence of genotypic resistance to nelfinavir among women exposed to prophylactic antiretroviral therapy during pregnancy.
Kakehasi FM; Tupinambás U; Cleto S; Aleixo A; Lin E; Melo VH; Aguiar RA; Pinto JA
AIDS Res Hum Retroviruses; 2007 Dec; 23(12):1515-20. PubMed ID: 18160009
[TBL] [Abstract][Full Text] [Related]
16. Influence of single-nucleotide polymorphisms in the multidrug resistance-1 gene on the cellular export of nelfinavir and its clinical implication for highly active antiretroviral therapy.
Zhu D; Taguchi-Nakamura H; Goto M; Odawara T; Nakamura T; Yamada H; Kotaki H; Sugiura W; Iwamoto A; Kitamura Y
Antivir Ther; 2004 Dec; 9(6):929-35. PubMed ID: 15651752
[TBL] [Abstract][Full Text] [Related]
17. Increased serum lipids are associated with higher CD4 lymphocyte count in HIV-infected women.
Floris-Moore M; Howard AA; Lo Y; Arnsten JH; Santoro N; Schoenbaum EE
HIV Med; 2006 Oct; 7(7):421-30. PubMed ID: 16925727
[TBL] [Abstract][Full Text] [Related]
18. Dyslipidaemia in HIV-infected patients: association with adherence to potent antiretroviral therapy.
Vergis EN; Paterson DL; Wagener MM; Swindells S; Singh N
Int J STD AIDS; 2001 Jul; 12(7):463-8. PubMed ID: 11394983
[TBL] [Abstract][Full Text] [Related]
19. Treatment durability, effectiveness, and safety with atazanavir/ritonavir-based HAART regimen in treatment-naïve HIV-infected patients.
Tremblay C; Trottier B; Rachlis A; Baril JG; Loutfy M; Lalonde R; Sampalis JS; Boulerice F
HIV Clin Trials; 2011; 12(3):151-60. PubMed ID: 21684855
[TBL] [Abstract][Full Text] [Related]
20. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS
Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
